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Abstract 
Duchenne Muscular Dystrophy is a devastating disease caused by the absence of a functional 
rod-shaped cytoplasmic protein called dystrophin. Several avenues are being developed aimed 
to restore dystrophin expression in boys affected by this X-linked disease. However, its complete 
cure is likely to need combinational approaches which may include regimes aimed at restoring 
muscle mass. Augmenting muscle growth through the manipulation of the Myostatin/Activin 
signalling axis has received much attention. However, we have recently shown that while 
manipulation of this axis in wild type mice using the sActRIIB ligand trap indeed results in 
muscle growth, it also had a detrimental impact on the testis. Here we examined the impact of 
administering a powerful Myostatin/Activin antagonist in two mouse models of Duchenne 
Muscular Dystrophy. We report that whilst the impact on muscle growth was not always positive, 
both models showed attenuated testis development. Sperm number, motility and ultrastructure 
were significantly affected by the sActRIIB treatment. Our report suggests that interventions 
based on Myostatin/Activin should investigate off-target effects on tissues as well as muscle. 
Key Words: Duchenne Muscular Dystrophy, Mdx, Muscle hypertrophy, Testis, Activin, 
Myostatin. 
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 Duchenne Muscular Dystrophy (DMD) is a genetic 
disease caused by the absence of a protein called 
Dystrophin.1 The dystrophin locus is found on the X-
chromosome, hence the disease manifests mainly in 
boys. It is a lethal disease characterised by progressive 
muscle weakness and wasting. As well as muscle damage 
and necrosis, a multitude of other cellular and tissue 
abnormalities play a role in the development of the 
pathology including inflammation, fibrosis and abnormal 
adiposity. Several treatments based on addressing 
mutations in the dystrophin gene mutations have/are 
being developed, including exon skipping and viral gene 
delivery therapies.2 The goal of most of the therapies is 
to modify DMD into a less severe disease called Becker 
Muscular Dystrophy. It is more than likely that 
combinational therapies (comprising gene correction 
strands and approaches to remedy abnormal tissues) are 
going to be needed to fully treat DMD/BMD. A major 
feature of both DMD and BMD is muscle wasting and 
contraction-induced damage.3 Several approaches are 
being developed to promote myogenesis for 
neuromuscular diseases and many of them focus on 
manipulating Myostatin signalling.4 Myostatin is a 
member of the TGF- family of secreted proteins and is 
a potent inhibitor of muscle development; genetic 
deletion in the mouse genome leads to massive degree of 
muscle enlargement mediated by the development of 
supernumerary muscle fibres (hyperplasia) as well as 
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fibre enlargement (hypertrophy).5 Myostatin and other 
closely related molecules including Activin activate 
intracellular signalling cascades by interacting with 
heterotetrameric receptor complex comprised of two 
Type I and two Type II receptors located on the cell 
surface. Myostatin/Activin signalling preferentially 
utilises the Type I receptors ALK4 or ALK7 and the Type 
II receptors  ACVR2A or ACVR2B (henceforth ActRIIA 
or ActRIIB, respectively).6 We and others have 
developed a ligand trap called the sActRIIB (capable of 
binding Myostatin and Activin) made of a stabilised form 
of the extracellular portion of the ActRIIB receptor and 
shown that it can promote considerable muscle growth 
(20-30%) in rodents in a relatively short period of time (4 
weeks).7 However, concerns stemming from the broad 
ligand binding nature of sActRIIB and the numerous 
tissue processes controlled by Activin remain, which 
could lead to unwanted side effects of its use to promote 
muscle development. Evidence to support such 
apprehensions have been reported in studies in non-
human primates in which changes to visceral organs 
(pancreas and spleen) developed following sActRIIB 
treatment.8 More recently we have reported that 
sActRIIB had a profound effect on the development of 
the mouse testis (9). We showed that muscle 
development promoted by sActRIIB was accompanied 
by a decrease in testis growth and furthermore that the 
beneficial effects of muscle growth were lost after the 
cessation of sActRIIB treatment, but the impairment in 
testis structure persisted.9 As treatments for DMD are 
being developed using molecules like sActRIIB, we 
investigated the impact of such an intervention in two 
mouse models for this disease. Here we show that 
although sActRIIB had differing degree of effects on 
muscle enlargement on the two mouse models of DMD, 
both showed abnormal testis development. Importantly 
we show that sActRIIB dramatically reduced sperm 
number  as well as inducing numerous ultrastructural 
abnormalities. 
Materials and Methods 
Ethical approval 
The experiments were performed under a United 
Kingdom Home Office project license, in agreement with 
the Animals (Scientific Procedures) Act 1986. The 
University of Reading Animal Care and Ethical Review 
Committee approved all procedures. Animals were 
humanely sacrificed via Schedule 1 killing.  
Animal maintenance 
All mice used were bred and maintained in accordance to 
the Animals (Scientific Procedures) Act 1986 (UK) and 
approved by the Biological Resources Unit of University 
of Reading. Post-natal Myostatin/Activin block was 
induced via intraperitoneal (IP) injection with 10mg/kg 
of sActRIIB-Fc (hereafter sActRIIB) twice weekly. The 
age of initial injection varied among different studies. All 
mice were obtained from Jackson laboratories and bred 
for pups. 
Histological analysis and immunohistochemistry 
Following dissection, testes were weighed and fixed in 
4% PFA prior to 4°C storage. PFA fixed testis were 
embedded in paraffin following a series of ethanol and 
histoclear stages. 8µm sections were cut using a Leica 
RM2155 rotary microtome prior to dewaxing in Xylene. 
Rehydration with ethanol stages was then performed 
prior to antigen retrieval in 0.01M citrate buffer pH6. 
Blocking buffer (10% FBS in TBS-Tx) was incubated on 
sections for 45 minutes at room temperature prior to 
incubation with primary antibody overnight at 4°C. 
Sections were subsequently washed in PBS-Tx three 
times prior to incubation with secondary antibody. 
Secondary antibodies attached to a fluorophore were 
Table 1. Antibody details 
Primary antibodies 
Antigen 
Species Dilution Supplier 
PCNA Mouse 1:200 Cell signalling Technology #25865 
PLZF (D-9) Mouse 1:250 Santa Cruz Biotechnology #sc-28319 
Stra8 Rabbit 1:1000 Abcam ab49405 
Sox9 Rabbit 1:1000 Abcam ab185966 
AQP3 Rabbit 1:800 Abcam ab125219 
Secondary antibodies Species Dilution Supplier 
AlexaFluor 488 anti-mouse Goat 1:200 Invitrogen 
Rabbit anti mouse IgG HRP Rabbit 1:200 DAKO #PO260 
Goat anti-rabbit IgG HRP Goat 1:5000 ThermoFisher scientific #65-6120 
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used for detection of all antibodies except PLZF and 
PCNA which were detected using the Vectastain ABC-
HRP kit with a Vector NOVARed HRP substrate. All 
primary antibodies being detected were subsequently 
incubated with a secondary antibody for 1hour at room 
temperature prior to detection. Details of primary and 
secondary antibodies are given in Table 1. 
Hematoxylin and eosin 
Testes sections were dewaxed in xylene prior to 
rehydration in ethanol stages. Harris haematoxylin 
solution (Sigma HHS16) was then incubated on the slides 
for 2 minutes prior to acidic alcohol and tap water for 
blueing. Eosin solution (Sigma-Aldrich 318906) was 
incubated on sections for 2 minutes prior to dehydration 
 
Fig 1. sActRIIB causes a reduction in testes weight and tubule areas in the Mdx mouse model of Duchenne Muscular 
Dystrophy. (A) Schematic of experimental design. Black arrows injection of 10mg/kg sActRIIB. Red arrows 
indicate time of cull. (B) Body weight at P69. (C) Gastrocnemius mass. (D) Teste mass. (E) Average tubule 
area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule. 
Immunostaining for (I) PCNA, (J) PLZF (K) Stra8 (L) Sox9 (M) AQP3. Quantification of (N) PCNA,  (O) 
PLZF (P) Stra8 (Q) Sox9 positive cells per tubule. (R) Quantification of AQP3 positive tubules as a percentage 
of total tubules.  n=3 PBS treated male mdx mice, n=3 sActRIIB treated male Mdx mice. Scale for all images 
represents 50µm. *p<0.05, ***<0.001. 
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in ethanol and clearing with xylene. Slides were mounted 
with a coverslip and DPX mounting media. 
Sperm motility studies 
70µl G-IVF PLUS (Vitrolife) was pipetted in two areas 
on to 35mm IVF Petri Dish (Thermo Scientific) and 
covered with mineral oil (Sigma-Aldrich M8410) prior to 
incubation at 37°C 5% CO2 for a minimum of 30 minutes 
prior to sperm isolation. Following schedule 1 killing, 
epididymis was dissected attached to the testes and 
placed in pre-warmed M2 medium (Sigma Aldrich). The 
epididymis was placed in to 70µl G-IVF PLUS bubble 
and cut to release the live spermatozoa. The cut 
epididymis was incubated at 37°C in 5% CO2 for 40 
minutes prior to 50µl being transferred to the second 
bubble of G-IVF PLUS media. Spermatozoa were 
imaged using Nikon Eclipse Ti-E Inverted Microscope at 
10x magnification with 3050 frames per minute captured. 
Analyses of spermatozoa speeds were determined using 
the manual tracking plugin in FIJI. Sperm concentrations 
were determined by fixing spermatozoa in 4% PFA prior 
to placing 10µl under a haemocytometer and imaged at 
20x magnification. 
Transmission electron microscopy 
For transmission electron microscopy, sperms were 
centrifuged and the resulting pellet embedded in 2% 
agarose. Afterwards, samples were contrasted using 1% 
osmium tetroxide (in PBS, 45 minutes at RT) and 1% 
uranyl acetate (45 minutes at RT in 70% ethanol). Agar 
blocks were dehydrated and embedded in epoxy resin 
(Durcupan, Sigma, Germany). Ultrathin sections were 
prepared using a Leica UC6 ultra-microtome and 
analysed using a Philipps CM100 TEM. 
Statistical analysis 
Data are presented as mean +/- SE. Significant 
differences between two groups were performed by the 
Student’s t-test for independent variables. Statistical 
analysis was performed on GraphPad Prism 5 with 
statistically significant differences considered at P<0.05. 
Results 
Impact of attenuation of Activin Receptor IIB signalling 
on the development of skeletal muscle and the testis of 
Mdx and DBA/2-Mdx mice 
We injected sActRIIB into Mdx mice from just after the 
onset of muscle necrosis (p21) until a stabilisation phase 
(p56) and collected tissues at p69 (Figure 1, A). There 
was no significant change in body weight induced by 
sActRIIB treatment (Figure 1, B). However, we found 
that sActRIIB had a profound impact on muscle growth, 
epitomized by the 36% increase in gastrocnemius mass 
(Figure 1, C). During the course of tissue recovery, we 
noticed that the testes were smaller in the sActRIIB 
treated group compared to those receiving vehicle (PBS) 
(Figure 1, D). In the treated Mdx mouse they were 17% 
lighter than in the untreated group. Thereafter we 
performed a histological and immunocytochemical 
analysis to identify the cellular and molecular changes 
underpinning the change in testis weight. In both the 
untreated and treated Mdx mice, the seminiferous tubules 
were readily identifiable with expected peritubular, basal, 
adluminal cellular distribution and lumen structures. 
Examination of the H and E images showed that the size 
of seminiferous tubules was smaller in the treated Mdx 
cohort which was substantiated following quantitative 
analysis (Figure 1, E and H). Lumen area was smaller in 
sActRIIB treated samples than those of controls (Figure 
1, F). The area of the cellular component of each tubule 
was measured and revealed that it was decreased by 
sActRIIB treatment (Figure 1, G). We next examined if 
the reduction in seminiferous tubule cross-section was 
caused by a decrease in cell proliferation. Visualisation 
of nuclear antigen (PCNA) expression, a marker for cell 
proliferation, demonstrated that these events were taking 
place adjacent to the basement membrane in both treated 
and untreated Mdx samples. Nevertheless, there were 
significantly fewer proliferating cells in the tubules of 
sActRIIB treated samples than in Mdx controls (Figure 1, 
I and N). Next, we quantified the number of 
spermatogonial stem cells (SSC) using the marker 
promyelocytic leukemia zinc finger (PLZF) since they 
give rise to the proliferating A and B type spermatogonial 
cells located within tubules.10  However, we were unable 
to detect any significant difference in the number of SSC 
per tubule between the two cohorts (Figure 1, J and O). 
Furthermore, we did not detect any difference in the 
ability of preleptotene spermatocyte to enter meiosis as 
demonstrated by Stimulated by Retinoic Acid 8 (Stra8) 
staining (Figure 1, K and P).11 Lastly, we quantified the 
number of Sertoli cells, identified by Sox9 expression,12 
which supports and thus ultimately limits the extent of 
spermatogenesis in each tubule and found no differences 
in this parameter between the sActRIIB treated Mdx 
group and untreated mice(Figure 1, L and Q). 
Importantly, the number of sperm tails (as detected either 
through H and E staining or immunostaining with sperm 
tail specific markers including Aquaporin3 (AQP3)13 was 
significantly reduced by sActRIIB treatment (Figure 1 M 
and R). Of note, there was no effect on Leydig cell 
numbers by sActRIIB treatment (data not shown). 
Although the mdx mouse has been extensively used for 
over 30 years since its full molecular characterization,14 
its pathology does not fully mirror the human condition. 
In recent years a more severe mouse model for Duchenne 
Muscle Dystrophy called the DBA/2-Mdx mouse has 
been developed as this strain displays a progressive 
dystrophy with greater degree of fibrosis and less muscle 
regeneration than the traditional Mdx mouse.15,16 We 
therefore examined the impact of sActRIIB on muscle 
and testis mass in the DBA/2-Mdx mouse.  Surprisingly 
we found that an identical regime of sActRIIB treatment 
in DBA/2-Mdx as the Mdx mouse resulted in a decrease 
in body mass (Figure 2 A-B). Interestingly, gross muscle 
mass was not increased by sActRIIB (Figure 2 C) but the 
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mass of the testis was decreased (Figure 2 D). In 
accordance to our finding in the Mdx mouse, sActRIIB 
had a profound effect on the seminiferous tubules in 
DBA/2-Mdx; with decreased in tubule as well as lumen 
areas and decreased in differentiation thickness (Figure 2 
E-G). Examination of key markers impacting on testis 
structure revealed that proliferation was attenuated as 
was the development of sperm tail (Figure 2 I and O and 
M and R). Identical to Mdx mice, treatment of DBA/2-
Mdx with sActRIIB had no effect on spermatogonial stem 
cells, meiosis or Sertoli cells (Figure 2 J-Q). Next, we 
assessed the impact of sActRIIB treatment on both the 
quantity and quality of mature sperm in the two genetic 
models of DMD. Quantification of sperm number 
revealed a decrease in sperm concentration of 62% in 
Mdx and 70% in DBA/2-Mdx (Figure 3 A-B). Sperm 
motility was also reduced by sActRIIB treatment in both 
mouse models (Figure 3 C-D). Ultra-structural sperm 
analysis in PBS treated Mdx and DBA/2-Mdx mice 
displayed normal spermatozoa with regular heads 
including elongated nuclei and acrosomes (Figure 4 A 
and F), longitudinal and cross-sections of midpieces 
 
 
Fig 2.  sActRIIB causes a reduction in testes weight and tubule areas in the DBA/2-Mdx mouse model of Duchenne 
Muscular Dystrophy. (A) Schematic of experimental design. Black arrows injection of 10mg/kg sActRIIB. Red 
arrows indicate time of cull. (B) Body weight at P69. (C) Gastrocnemius mass. (D) Teste mass. (E) Average 
tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule. 
Immunostaining for (I) PCNA, (J) PLZF (K) Stra8 (L) Sox9 (M) AQP3. Quantification of (N) PCNA, (O) 
PLZF (P) Stra8 (Q) Sox9 positive cells per tubule. (R) Quantification of AQP3 positive tubules as a percentage 
of total tubules.  n=5 PBS treated male DBA/2-Mdx mice, n=5 sActRIIB treated male DBA/2-Mdx mice. Scale 
for all images represents 50µm. *p<0.05, ***<0.001. 
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(Figure 4 A) including mitochondrial sheaths as well as 
tails (Figure 4 A) with regular axoneme. sActRIIB 
treatment in Mdx mice leads to a significant reduction of 
normal spermatozoa (Figure 4 E). Instead, we found a lot 
of cell debris (Figure 4 B, C), cytoplasm rich round cells 
(Figure 4 B-C) and large cells with atypical nuclear shape 
and doubling of organelles (Figure 4D). DBA/2-Mdx 
mice sActRIIB treatment resulted in a comparable 
phenotype. Only very few normal spermatozoa were 
found. Instead, cytoplasm rich pleomorphic (Figure 4 G, 
I and J) and round cells with malformed cell organelles 
(Figure 4 G-H) e.g. nuclei (Figure 4 H, I and J) were 
detected. 
Discussion 
Regimes to promote muscle growth are likely to feature 
in combinational therapies that aim to cure patients with 
neuromuscular diseases. However, it is likely they will 
need careful optimisation before they can reach their 
intended milestones due in many cases to factors that 
cause the disease. One recent example was highlighted in 
an elegant study which showed that the muscle growth 
properties of myostatin inhibition could be effectively 
eliminated by glucocorticoids, drugs that are often used 
to control inflammation in diseases including DMD. Here 
we highlight the need to optimise the use of muscle 
growth regimes due to side effects on the development of 
the testis. This study adds to a growing body of evidence 
that Myostatin/Activin neutralisation impacts on non-
muscle tissues exemplified by a clinical trial in patients 
with DMD of the soluble Activin ligand trap ACE-031 
which was halted due to telangiectasias and epistaxis.17 
Here we show that sActRIIB had a profound impact on 
testis mass and  both quantitatively and qualitatively on 
sperm in two mouse models of DMD; sActRIIB 
decreased the number of sperm and those that formed 
often had abnormal structure, including duplication of 
mid-piece organelles. Interestingly the sActRIIB did not 
have the same impact on muscle mass in both models; 
Mdx showed an increase in this parameter whereas 
DBA/2-Mdx failed to respond to any significant levels. 
However, this result may be misleading since the DBA/2-
Mdx muscle is very fibrotic and contain a substantial 
osteogenic component.15. Myostatin as well as Activin 
are known to promote fibrosis and therefore it is possible 
that following sActRIIB treatment, there is a concurrent 
decrease in fibrosis and increase in muscle content.18 
Indeed, a detailed examination of the structure of 
sActRIIB treated DBA/2-Mdx muscle supports this 
thinking (manuscript in preparation).  
 
Fig 3. sActRIIB causes a reduction in sperm concentration and speed in the Mdx and DBA/2-Mdx mouse model of 
Duchenne Muscular Dystrophy. (A) Sperm concentration in the Mdx mouse model. (B) Sperm concentration 
in the DBA/2-Mdx mouse model. (C) Sperm speed in the Mdx mouse model. (D) Sperm speed in the DBA/2-
Mdx mouse model. n=3 PBS treated male DBA/2-Mdx mice, n=3 sActRIIB treated male DBA/2-Mdx mice. 
*p<0.05, ***<0.001.  
 
Impaired spermatogenesis in Mdx and DBA/2-Mdx mice by myostatin-based interventions 
Eur J Transl Myol 30 (2): xx1-x10, 2020 
- 7 - 
 
In some ways, sActRIIB acts as endogenous ligand traps 
for Myostatin and Activin such as Follistatin (FST) and 
Follistatin-like 3 (FSTL3, also identified as Follistatin 
Related Protein or Follistatin Related Gene,19,20 which 
sequester the ligands and prevent them from interacting 
with the membrane bound signalling receptors.21 The 
biochemistry, and associated biology, of these two 
molecules reveal a large degree of similarity as well as 
crucial differences. Importantly, in both human and 
mouse serum, Myostatin was found to be in a complex 
with FSTL3 and not FST.22 Moreover, the expression 
pattern of these two ligand traps are different and of the 
two FSTL3 is more relevant to the testis.23 Importance of 
FSTL3 in testicular biology is highlighted by in vivo 
models. Overexpression using a transgenic approach 
reduces testis size and sperm count,24 mirroring sActRII 
injection studies. Contrastingly, FSTL3 deletion 
increases testicular size and prolongs the span 
spermatogenesis.25 Finally, both FST and FSTL3 mRNA 
and protein increases in response to Activin,26 setting up 
a feedback inhibitory loop for activin action. Given that, 
sActRIIB reduces Myostatin/Activin signalling and 
therefore FSTL3 expression is not likely to increase in 
the testis in this model, hence the effect of sActRIIB on 
inhibiting testicular development and function is also not 
likely due to the induction or overexpression of FSTL3. 
Many of the side effects of ligand trap treatments could 
possibly be attributed to the ability of the molecule to 
interact with proteins other than Myostatin and Activin 
and the specific model in which the they are deployed. 
For example, the incidence of bleeding attributed to 
ACE-031 could be due to its interaction with BMP9, 
which has been shown to regulate endothelial cell 
function.27 It is intriguing that ACE-031 induced 
bleeding in DMD boys whereas no bleeding issues were 
noted in our use of sActRIIB in mice. We suggest that 
each molecule, due to specific (and potentially 
proprietorial) modifications may harbour unique ligand 
binding kinetics which implies that each iteration should 
be experimentally evaluated in individual target 
organisms rather than relying on anecdotal data. 
Alternatively, the side-effects could be attributed to 
interfering with the large number of processes that are 
regulated by Activin. One would predict that any 
mechanism that delivers the same outcome of robust dual 
Myostatin/Activin inhibition could also lead to unwanted 
side effects. In this respect, one would that regimes used 
to block the ActRIIB receptor (e.g. Bimagrumab)28 to be 
equivalent to the sActRIIB molecule used in this study, 
with the same outcomes in terms of tissue development. 
However the effects we report on the testis were not 
observed or reported following the use of Bimagrumab.29 
We suggest that in future the side-effects could be limited 
by either i) using lower doses of the Myostatin/Activin 
blocker, ii) using a targeted approach that neutralises 
Myostatin and Activin only in the circulation or iii) 
targeting either only Myostatin or Activin but not both. 
We believe for muscle wasting therapies, it may not be 
necessary to use the high doses of sActRIIB which are 
used in experimental work since the intended outcomes 
are different. In the former, the point is to stop muscle 
mass from decreasing, whereas in the latter proof of 
principle requires robust muscle growth, typically 30-
50% in two weeks. The second point relates to targeting 
the molecules that need to be neutralised while sparing 
those performing essential functions. It is worth drawing 
 
Fig 4. Ultra-structure of sperm from mouse models of DMD. Mdx sperm treated with PBS show normal head 
structure with elongated nuclei and acrosomes (asterisk), midpieces (longitudinal-section (red arrow) and 
cross-sections (blue arrows)) mitochondrial sheaths and tail segments (arrowhead). (B-E) Mdx treated with 
sActRIIB. (E) A few normal sperm with usually elongated nuclei (asterisk) and midpiece (red arrow). (B-C) 
Presence of cell debris was prominent (arrow heads) and cells with large cytoplasmic component (red 
arrowheads). (D) Sperm with atypical nuclear shape and doubling of organelles (asterisk and arrows). (F) 
DBA/2-Mdx sperm treated with PBS show normal head structure with elongated nuclei and acrosomes 
(asterisk), longitudinal (red arrow) and tails (arrowhead). (G-H) DBA/2-Mdx treated with sActRIIB. Large 
pleomorphic cells filled with cytoplasm (G, I, J) and (H) round cells with malformed organelle (arrow) and 
nuclei (H, I, J asterisks). 
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parallels from the work conducted using Follistatin to 
promote muscle growth. The group of Mendell has 
specifically deployed a form of Follistatin (FS315) to 
neutralise circulating Myostatin/Activin while sparing 
molecules working in the extracellular matrix (ECM) 
which results in significant muscle growth but no issues 
related to the reproductive system.30 Our study induced 
both a muscle phenotype and one related to the 
reproductive system. This implies that sActRIIB can 
neutralise both the circulating ligands and those 
associated with the ECM. Future efforts should be made 
to modify sActRIIB’s ability to interact with the ECM. 
The last point relates to targeting Myostatin alone as 
opposed to both Myostatin and Activin. This will 
undoubtedly be less potent in terms of muscle growth. 
However, it may be adequate when the desired outcome 
is the prevention of muscle wasting, rather than 
promotion of growth.  
The results presented in this study are supported by likely 
on-target effect for an intervention that inhibits Activin.31 
To our knowledge, no other study has reported a similar 
undesired side-effect of using a similar molecule. Indeed, 
many studies fail to mention whether this organ was ever 
investigated. Given the severity of sActRIIB phenotype 
on the testis in the two mouse models of DMD, we 
suggest that it is essential that they should be studied not 
only in clinical trials but also in other model systems 
when a similar regime is being deployed.  
Our study counsels caution to the use of robust anti-
myostatin based therapies developed to promote muscle 
growth, especially those that simultaneously neutralise 
the activity of both Activin and Myostatin. Furthermore, 
we note that other non-skeletal muscle conditions are 
being targeted using molecules almost identical to that 
used here. For example, an ActRIIB ligand trap called 
ACE-536 which is marketed under the tradename 
Reblozyl for the treatment of anaemia patients with beta 
thalassemia.32 This molecule has been shown to be a 
potent binder of both Myostatin and GDF-11 (32). 
However, recent work suggests that the ability of ACE-
536 to promote terminal erythropoiesis may be 
independent of GDF-11 binding.33 We suggest that long 
term use of this molecule should be tested first in animal 
models for its impact on testis development. 
In summary, we show in two mouse models of DMD that 
attenuation of Myostatin/Activin signalling using 
sActRIIB leads to a testicular phenotype which impacts 
on the structure of the organ as well as the quantity and 
quality of sperm. A debate needs to be initiated if the 
benefits in terms of muscle growth outweigh this and 
possible other side-effects when using a molecule for the 
treatment of young boys with DMD. 
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PBS-Tx - Phosphate buffered Salines with Triton X100 
PCNA - Proliferating cell nuscler antigen 
PLZF - Promyelocytic Leukemia Zinc Finger 
RT – room temperature 
sActRIIB-Fc = sActRIIB 
Sigma HHS16 - Harris haematoxylin solution 16 
Sox9 - SRY Box transcription factor 9 
Stra8 - Stimulated By Retinoic Acid 8 
TGF - Transforming Growth Factor beta 
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